MSH2 and cancer: In the hMSH2 gene, the mutation prevalence ranged from 17.56% to 33.78% in the AC+ group, from 10.33% to 20.60% in the AC− group and from 3.64% to 21.90% in the sporadic cancer group (AC+: P = 0.00<0.05; AC−: P = 0.91>0.05; sporadic: P = 0.00<0.05) in the four ethnicities evaluated.